Learn more

Grünenthal GmbH

Overview
  • Total Patents
    536
  • GoodIP Patent Rank
    5,975
  • Filing trend
    ⇩ 90.0%
About

Grünenthal GmbH has a total of 536 patent applications. It decreased the IP activity by 90.0%. Its first patent ever was published in 1996. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and machines are LIGAND PHARMACEUTICALS INCORPORATED, KISSEI FARMAS JUTIKAL KO LTD and G D SEARLE & AMP.

Patent filings per year

Chart showing Grünenthal GmbH s patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Bahrenberg Gregor 71
#2 Barnscheid Lutz 70
#3 Schröder Wolfgang 58
#4 Kless Achim 50
#5 Wening Klaus 49
#6 Kühnert Sven 48
#7 Bartholomäus Johannes 46
#8 Jakob Florian 45
#9 Christoph Thomas 43
#10 Schiene Klaus 40

Latest patents

Publication Filing date Title
US2018042868A1 Tamper resistant formulation of ephedrine and its derivatives
WO2018007507A1 Reinforced pharmaceutical dosage form
US2017273970A1 Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders
WO2017182425A1 Pharmaceutical dosage form mountable to a tooth
US2017296476A1 Modified release abuse deterrent dosage forms
US2017112766A1 Tamper-resistant dosage form with immediate release and resistance against solvent extraction
WO2017108203A1 Novel substituted indoline compounds as phosphodiesterase inhibitors
WO2017114596A1 Crystalline forms of (cis)-n-(4-(dimethylamino)-1,4-diphenylcyclohexyl)-n-methyl-cinnamamide
WO2017114597A1 Pharmaceutical dosage forms comprising ((cis)-n-(4-(dimethylamino)-1,4- diphenylcyclohexyl)-n-methylcinnamamide
WO2017021397A1 Phase separator
WO2016180543A1 In vitro screening assay for thermoneutral trpv1 modulators
EP3286196A1 Crystalline salts of hydrocodone bitartrate
AU2016251851A1 Tamper-resistant fixed dose combination providing fast release of two drugs from particles
WO2016096140A1 Process for the preparation of 1-[(heteroaryl)-methyl]- or 1-[(aryl)-methyl]-3-[4-(hydroxymethyl)-phenyl]-ureas
EP3130590A1 Aromatic aza compounds as vr1/trpv1 ligands
EP3130589A1 Heterocyclic aza compounds
US2016016937A1 Substituted pyrimidine compounds
AR101198A1 PYRIMIDINES 2,5-REPLACED AS PDE4B INHIBITORS
AR101197A1 PYRIMIDINES 2,5-REPLACED
WO2015197188A1 Pyrazolyl-based carboxamides as crac inhibitors